NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 American Society of Clinical Oncology Annual Meeting

Rhea-AI Summary

NexImmune (Nasdaq: NEXI), a clinical-stage biotechnology company, announced the presentation of data from its Phase 1/2 study of NEXI-001 at the ASCO 2021 Annual Meeting, scheduled for June 4-8, 2021. The clinical trial focuses on the treatment of relapsed acute myeloid leukemia (AML) post-hematopoietic cell transplantation. The study aims to utilize NexImmune's proprietary AIM nanoparticle technology to enhance the immune response.

Positive

• NEXI-001 is advancing in a Phase 1/2 clinical trial for relapsed AML, indicating ongoing development and potential market impact.
• Presentation at ASCO 2021 could enhance visibility and credibility in the oncology field.

Negative

• None.

GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually from June 4 – June 8, 2021.

Poster Presentation:

Title: Preliminary Analysis of a Phase 1/2 Study of NEXI-001 Donor-Derived Multi-Antigen-Specific CD8+ T Cell Treatment of Relapsed Acute Myeloid Leukemia (AML) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Abstract #: 2538

Session Title: Poster Session: Developmental Therapeutics – Immunotherapy

Authors: Monzr M. Al Malki, MD¹, Sumithira Vasu, MBBS², Dipenkumar Modi, MD³, Miguel-Angel Perales, MD⁴, Megan Nelson, RN, BSN⁵, Donna Bui¹, Vineetha Edavana, PhD⁶, Sojung Kim, PhD⁶, Lauren Suarez, PhD⁶, Mathias Oelke, PhD⁶, Robert D. Knight, MD⁶, and Juan C. Varela, MD, PhD⁵

(1) Hematology/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA, (2)Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, (3)Division of Oncology, Karmanos Cancer Center/ Wayne State University, Detroit, MI, (4)Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, (5)Advent Health Blood and Marrow Transplant Program, Orlando, FL, (6)NexImmune Inc, Gaithersburg, MD.

About NexImmune

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to 3 or more prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

For more information, visit www.neximmune.com.

Forward Looking Statements

This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our planned and ongoing clinical studies for the Company’s product candidates, including NEXI-001 and NEXI-002; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

Contacts

Investors and Media:
Chad Rubin, SVP Corporate Affairs
NexImmune, Inc.
646.319.3261
crubin@neximmune.com

FAQ

What is the goal of the NEXI-001 clinical trial?

The NEXI-001 clinical trial aims to treat relapsed acute myeloid leukemia (AML) after hematopoietic cell transplantation using a novel immunotherapy approach.

When will the NEXI-001 study data be presented?

The data from the NEXI-001 study will be presented at the ASCO 2021 Annual Meeting from June 4 to June 8, 2021.

How does NexImmune's AIM technology work?

NexImmune's AIM technology uses nanoparticles that act as synthetic dendritic cells to specifically engage and expand T cells, aiming for a targeted immune response.

What are the implications of the ASCO presentation for NexImmune?

The ASCO presentation could lead to increased investor interest and validation of NexImmune's clinical approach, impacting stock performance positively.